Agenus Inc., an immuno-oncology company, focuses on the discovery and development of treatments that engage the body's immune system for patients suffering with cancer. The company offers Retrocyte Display, an antibody discovery platform that screens and generates therapeutic antibody drug candidates using a high-throughput approach incorporating human antibody libraries expressed in mammalian B-lymphocytes. It is also developing Prophage, a heat shock protein-based autologous vaccine, which has completed Phase II clinical trials for the treatment of glioblastoma; and QS-21 Stimulon, a saponin-based vaccine adjuvant that has completed Phase III clinical trials for the treatment of malaria and shingles. The company's preclinical development products include AutoSynVax, a neo-antigen based vaccine targeting the neo-epitope landscape in cancer patients; PhosphoSynVax, a vaccine candidate designed to induce immunity against a novel class of tumor specific neo-epitopes; and checkpoint modulator product candidates targeting GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1, CEACAM1, and other undisclosed targets. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Agenus reports 3Q loss LEXINGTON, Mass. (AP) _ Agenus Inc. (AGEN) on Thursday reported a loss of $40.8 million in its third quarter. The Lexington, Massachusetts-based company said it had a loss of 47 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 32 cents per share. The biotechnology company posted revenue of $4.4 million in the period, which also fell short of Street forecasts. Three analysts surveyed by Zacks expected $6.2 million. Agenus shares have increased 15 percent since the beginning of the year. The stock has climbed nearly 5 percent in the last 12 months.
